View More Recent Stories

Mar 23, 2023 02:00AM Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update
Mar 23, 2023 02:00AM Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update
Nov 5, 2020 08:00AM Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients
Aug 11, 2020 01:00AM Innate Pharma Obtains €6.8M in Public Funding for Its COVID-19 Research And Development Activities
Nov 14, 2016 06:26AM Bristol-Myers Squibb (BMY), Innate Pharma SA Announce Encouraging Data from lirilumab and Opdivo Phase 1/2 in SCCHN Cohort
Nov 12, 2016 11:18AM Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (Nivolumab)
Nov 12, 2016 11:15AM Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck
Oct 9, 2016 07:46AM Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress
Oct 9, 2016 07:00AM Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress
View More Recent Stories